Patients with advanced or recurrent cancers who have tested positive for BRCA mutations are prime candidates for PARP inhibitor therapy. Genetic testing is crucial in identifying these patients. In some cases, patients without BRCA mutations but with other defects in DNA repair pathways may also benefit from these drugs.
